There has been tremendous growth and innovation in recent years with PET being routinely used in clinical diagnosis and staging as well as monitoring of cancer treatment. Additionally, PET has become a very robust tool in clinical trials, where the use of PET follows two distinct approaches: qualitative assessment and quantitative assessment.

A typical qualitative assessment may focus on the overall visual assessments of activity on whole body scans, while quantitative assessment requires a high degree of analysis and dedication on the part of the clinical site performing PET scans and upon the reader evaluating those images in the context of the extent of disease and response following therapy.

Here we explore the use of PET in oncology clinical trials.